Endocrine signaling research
Ipamorelin
Lyophilized endocrine-signaling research peptide for systems review
Ipamorelin is a selective growth hormone secretagogue receptor research peptide used in GH-release and endocrine-signaling comparisons.
This product has an available COA with reported batch details and test results.
Open available COAConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesFor laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, mitigate, or prevent disease.
Keep sealed, cold, dry, and protected from heat swings. Confirm product-specific storage on arrival.
Packed for transit stability with order support available for warm-weather routes.
Batch-linked certificate support is available through the documentation desk.
Research context
Ipamorelin research profile
Ipamorelin is a pentapeptide growth hormone secretagogue studied for activity at the ghrelin receptor, also known as GHS-R1a. Experimental work compares GH-release response, pharmacokinetics, receptor selectivity, and effects on other endocrine markers with older secretagogues such as GHRP-2, GHRP-6, and hexarelin. It differs from CJC-1295 and sermorelin because those compounds act through the GHRH receptor rather than GHS-R. Ipamorelin is therefore a focused choice for secretagogue and receptor-selectivity studies, either alone or as a comparator in GH-axis designs. Early human PK/PD literature exists, but it does not validate a research-use catalog lot.
Proposed mechanism
A pentapeptide agonist at the growth-hormone secretagogue receptor GHS-R1a. Receptor activation engages Gq-related signaling in pituitary and hypothalamic systems and stimulates growth-hormone release.
Effects reported in studies
- Animal and human pharmacology studies reported dose-dependent GH release after ipamorelin exposure.
- Comparative studies described greater GH selectivity and less ACTH or cortisol stimulation than some older GHRP compounds under studied conditions.
- It remains a ghrelin-receptor agonist, and selectivity does not mean absence of all off-target or systemic effects.
Common research endpoints
GHS-R1a potency, calcium or second-messenger response, GH concentration and pulse shape, ACTH, cortisol, prolactin, appetite markers, pharmacokinetics, and desensitization.
Evidence and limitations
Preclinical and early controlled human PK/PD evidence exists. Long-term human outcomes and equivalence of catalog material are not established.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Open the available COA on this page. Before ordering, confirm the named material and listed format; when the order arrives, match the document identifiers to the supplied lot.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.